Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Blood (2023) 141 (13): 1584–1596.

https://doi.org/10.1182/blood.2022016934

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

Ibrutinib-Associated Sudden Death in Patients with CLL

Emily Bryer, Andy Itsara, Inhye E. Ahn, Beth Kozel, Cody Peer, William D. Figg, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 4133–4134.

https://doi.org/10.1182/blood-2022-160397

Published: 2022

Journal Articles

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Andy Itsara, Clare Sun, Inhye E. Ahn, Susan Soto, Douglas Rosing, Mark Haigney, Adrian Wiestner

Blood (2022) 140 (Supplement 1): 4169–4170.

https://doi.org/10.1182/blood-2022-159716

Published: 2022

Journal Articles

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Maissa Mhibik, Erika M. Gaglione, David Eik, Ellen K. Kendall, Amy Blackburn, Keyvan Keyvanfar, Maria Joao Baptista, Inhye E. Ahn, Clare Sun, Junpeng Qi, Christoph Rader, Adrian Wiestner

Blood (2021) 138 (19): 1843–1854.

https://doi.org/10.1182/blood.2020009686

Published: 2021

Includes: Supplemental data

Journal Articles

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar, Jennifer A. Woyach

Blood (2021) 138 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2021-153822

Published: 2021

Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf

Blood (2021) 138 (Supplement 1): 2634.

https://doi.org/10.1182/blood-2021-153033

Published: 2021

Journal Articles

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun

Blood (2021) 138 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2021-148539

Published: 2021

Journal Articles

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander R. Coltoff, Matthew S. Davids, Peter O. Baker, Lori Leslie, Kerry A. Rogers, John N. Allan, Raul Cordoba, Alberto Lopez-Garcia, Darko Antic, John M. Pagel, Nicolas Martinez-Calle, José Antonio García-Marco, Jose‐Ángel Hernández‐Rivas, Fatima Miras, Catherine C. Coombs, Anders Österborg, Lotta Hansson, Amanda N. Seddon, Javier López Jiménez, Matthew R. Wilson, Dima El-Sharkawi, Daniel Wojenski, Shuo Ma, Talha Munir, Susana Valenciano, Erlene Seymour, Paul M. Barr, Jeffrey Pu, Piers E. M. Patten, Guilherme F. Perini, Scott F. Huntington, Helen Parry, Suchitra Sundaram, Alan Skarbnik, Manali Kamdar, Ryan Jacobs, Harriet Walter, Renata Walewska, Angus Broom, Sonia Lebowitz, Krista M. Isaac, Craig A. Portell, Inhye E. Ahn, Chaitra S. Ujjani, Mazyar Shadman, Sigrid S. Skånland, Elise A. Chong, Anthony R. Mato

Blood (2021) 138 (18): 1768–1773.

https://doi.org/10.1182/blood.2021011841

Published: 2021

Includes: Supplemental data

Journal Articles

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Christopher Pleyer, Mir A. Ali, Jeffrey I. Cohen, Xin Tian, Susan Soto, Inhye E. Ahn, Erika M. Gaglione, Pia Nierman, Gerald E. Marti, Charles Hesdorffer, Jennifer Lotter, Jeanine Superata, Adrian Wiestner, Clare Sun

Blood (2021) 137 (2): 185–189.

https://doi.org/10.1182/blood.2020008758

Published: 2021

Includes: Supplemental data

Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134386

Published: 2020

Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134431

Published: 2020

Journal Articles

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F. Huntington, Matthew S. Davids, Jennifer R. Brown, Darko Antic, Ryan Jacobs, Inhye E. Ahn, Jeffrey Pu, Krista M. Isaac, Paul M. Barr, Chaitra S. Ujjani, Mark B. Geyer, Ellin Berman, Andrew D. Zelenetz, Nikita Malakhov, Richard R. Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme F. Perini, Shuo Ma, Christine E. Ryan, Adrian Wiestner, Craig A. Portell, Mazyar Shadman, Elise A. Chong, Danielle M. Brander, Suchitra Sundaram, Amanda N. Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew R. Wilson, Piers E. M. Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S. Skånland, Raul Cordoba, Toby A. Eyre

Blood (2020) 136 (10): 1134–1143.

https://doi.org/10.1182/blood.2020006965

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Blood (2020) 136 (1): 93–105.

https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

Cardiovascular adverse events of ibrutinib

Inhye E. Ahn

Blood (2019) 134 (22): 1881–1882.

https://doi.org/10.1182/blood.2019002805

Published: 2019

Journal Articles

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Christopher Pleyer, MD, Jeffrey Cohen, MD, Susan Soto, Mir Ali, PhD, Inhye E Ahn, MD, Pia Nierman, BSN, MA, RN, Janet Valdez, Jennifer Lotter, PA-C, Jeanine Superata, RN, Xin Tian, Adrian Wiestner, MD PhD, Clare Sun, MD

Blood (2019) 134 (Supplement_1): 3053.

https://doi.org/10.1182/blood-2019-121675

Published: 2019

NARROW

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Ibrutinib-Associated Sudden Death in Patients with CLL

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Cardiovascular adverse events of ibrutinib

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only